AIRNA is developing RNA editing therapies to treat rare and common diseases by precisely modifying RNA sequences to correct genetic mutations. This approach aims to enhance patient health outcomes by targeting the underlying causes of genetic disorders.

The startup develops radiopharmaceuticals that utilize proprietary imaging and therapeutic molecules to enhance the diagnosis and treatment of metastatic cancer. By targeting both solid and hematologic malignancies, the company provides healthcare professionals with differentiated treatment options that aim to extend patient survival while maintaining favorable safety profiles.

Alterome Therapeutics, Inc. develops alteration-specific small molecule therapies using a structure-guided machine learning platform to target validated oncogenic drivers in cancer patients with limited treatment options. The company aims to provide precise therapeutic solutions that improve patient outcomes and inspire hope in the fight against cancer.

Alumis develops oral therapies using a precision medicine approach to target immune-mediated diseases, focusing on the underlying drivers of immune dysfunction through genetic and translational insights. The company aims to improve clinical outcomes for patients suffering from autoimmune disorders by optimizing therapeutic interventions.

AmbAgon Therapeutics develops targeted cancer molecule therapeutics that utilize specific molecular pathways to inhibit tumor growth. The company focuses on providing effective treatment options for patients with various types of cancer, addressing the need for more precise and less toxic therapies.

Arrakis Therapeutics is developing RNA-targeted small molecule therapeutics to address neurological disorders and other diseases by utilizing a novel RNA degradation approach. Their focus on rSM medicines aims to improve treatment efficacy and patient outcomes in complex disease areas.

ARS Pharmaceuticals develops neffy, the first FDA-approved needle-free epinephrine nasal spray, providing a portable and easy-to-use alternative for individuals at risk of severe allergic reactions. This product addresses the challenges of needle-related risks and the anxiety associated with traditional epinephrine delivery methods.

Arvinas uses a proprietary PROTAC discovery engine to design bifunctional molecules that recruit E3 ubiquitin ligases and trigger proteasomal degradation of disease‑relevant proteins, expanding the druggable proteome for oncology and neurodegenerative indications. The company advances clinical‑stage degraders and offers partnership models for pharmaceutical and biotechnology companies to co‑develop or license these targeted protein‑degradation therapeutics.

Atavistik Bio uses its proprietary Atavistik Metabolite‑Protein Screening (AMPS) platform to discover and develop precision allosteric small‑molecule therapeutics by identifying cryptic allosteric pockets with metabolite‑guided and AI‑enabled methods. The integrated computational‑experimental workflow accelerates hit identification and lead optimization for high‑unmet‑need targets in oncology and rare diseases, enabling partners to drug previously intractable proteins with improved selectivity and tolerability.

Attovia is developing a pipeline of biotherapeutics for immune-mediated diseases and oncology using its proprietary ATTOBODY platform, which enables the creation of bispecific and multispecific antibodies with picomolar affinity and enhanced tissue penetration. This technology addresses the lack of effective treatment options for patients by providing first-in-class mechanisms of action that improve therapeutic efficacy.

Be Biopharma is developing engineered B cell therapies to treat serious diseases, focusing on conditions like hemophilia B. Their approach utilizes protein-based treatments to enhance patient outcomes and improve quality of life for those affected.

Black Diamond Therapeutics develops MasterKey therapies that target genetically defined cancers, specifically non-small cell lung cancer and glioblastoma, by addressing multiple oncogenic mutations with a single treatment approach. This technology aims to overcome resistance mechanisms and reduce toxicities associated with wild-type proteins, enhancing treatment efficacy for a broader patient population.

Boundless Bio is a precision oncology company developing ecDNA-directed therapies (ecDTx) to target oncogene amplified cancers, which affect over 5 million patients annually and currently lack effective treatment options. By leveraging their proprietary Spyglass platform, Boundless Bio identifies and exploits the vulnerabilities associated with extrachromosomal DNA, a key mechanism driving tumor growth and resistance to existing therapies.

C4 Therapeutics develops targeted protein degradation therapies that specifically eliminate disease-causing proteins, utilizing a proprietary approach to induce selective protein removal. This technology aims to address the underlying causes of diseases, potentially transforming treatment outcomes for patients with conditions linked to dysfunctional proteins.

CARGO Therapeutics is developing tri-specific CAR T-cell therapies designed to target and eliminate B-cell lymphoma cells effectively. This approach aims to provide patients with potentially curative treatment options that traditional therapies may not achieve.

Circle Pharma designs and develops bioavailable macrocyclic peptide therapeutics targeting intracellular protein-protein interactions, particularly those involved in cancer. Their computational structure-based design approach combines physics-based conformational modeling and innovative chemistry to create permeable macrocyclic peptide drug candidates.

Context Therapeutics is developing T cell engaging bispecific antibody therapies targeting solid tumors, utilizing specific mechanisms such as Claudin 6, Mesothelin, and Nectin-4 to enhance T cell activation against cancer cells. Their approach aims to improve treatment efficacy for patients with difficult-to-treat solid tumors, addressing the limitations of current therapies.

Delphia is developing a precision medicine platform that utilizes activation lethality to exploit the vulnerability of cancer cells through oncogene overactivation. This approach aims to create effective cancer therapies that reduce the risk of resistance mutations commonly seen with traditional targeted treatments.

Exo Therapeutics utilizes its ExoSight™ platform to identify and develop small molecule inhibitors targeting exosites on enzymes involved in oncology and inflammation. This approach aims to enhance the modulation of enzyme activity, addressing the challenge of drugging previously inaccessible targets.

Flare Therapeutics utilizes a novel approach to target switch sites on transcription factors, enabling the development of small molecule medicines that can precisely modulate gene expression. The company focuses on creating therapies for precision oncology by addressing the challenges of drugging previously inaccessible transcription factors.

The startup has developed a synthetic biology platform that utilizes genomics and data science to identify small molecule inhibitors from fungal genomes. This technology enables researchers to discover new medicines encoded in the global metagenome, addressing the need for innovative therapeutic solutions.

IconOVir Bio is developing oncolytic virus therapy to target and destroy cancer cells while sparing healthy tissue. This approach aims to improve treatment outcomes for patients with various types of cancer by harnessing the body's immune response.

IDEAYA Biosciences develops targeted therapeutics for genetically-defined cancers using synthetic lethality, a method that exploits specific genetic alterations in tumors to induce cancer cell death. By employing molecular diagnostics, the company aims to create first-in-class treatments that address the unmet needs of patients with complex cancer profiles.

IDRx is developing IDRX-42, an oral KIT tyrosine kinase inhibitor targeting specific mutations in gastrointestinal stromal tumors (GIST) to enhance treatment efficacy. The company addresses the significant unmet medical need for effective therapies in GIST, where current standards of care have remained unchanged for nearly two decades.